Immuneering touts 64% 1-year survival, keeping wheels turning in race with Revolution
Fuente:
FierceBiotech
Immuneering has reported updated data on atebimetinib in first-line pancreatic cancer patients, linking the MEK inhibitor to 64% overall survival at 12 months.